Biosynex SA
PAR:ALBIO

Watchlist Manager
Biosynex SA Logo
Biosynex SA
PAR:ALBIO
Watchlist
Price: 0.5 EUR 2.88% Market Closed
Market Cap: 9.4m EUR

Profitability Summary

Biosynex SA's profitability score is hidden . We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
Biosynex SA

Revenue
98m EUR
Cost of Revenue
-40.3m EUR
Gross Profit
57.6m EUR
Operating Expenses
-121.4m EUR
Operating Income
-63.8m EUR
Other Expenses
-7.2m EUR
Net Income
-71m EUR

Margins Comparison
Biosynex SA Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
FR
Biosynex SA
PAR:ALBIO
9.2m EUR
59%
-65%
-72%
US
Abbott Laboratories
NYSE:ABT
210.2B USD
56%
18%
32%
US
Intuitive Surgical Inc
NASDAQ:ISRG
199.7B USD
66%
29%
29%
US
Boston Scientific Corp
NYSE:BSX
136.4B USD
69%
19%
14%
US
Stryker Corp
NYSE:SYK
133.6B USD
65%
22%
12%
IE
Medtronic PLC
NYSE:MDT
129.1B USD
66%
19%
14%
DE
Siemens Healthineers AG
XETRA:SHL
48.4B EUR
39%
14%
9%
US
IDEXX Laboratories Inc
NASDAQ:IDXX
56.2B USD
62%
31%
25%
US
Becton Dickinson and Co
NYSE:BDX
54.6B USD
46%
16%
8%
US
Edwards Lifesciences Corp
NYSE:EW
48.7B USD
78%
28%
23%
US
GE Healthcare Technologies Inc
NASDAQ:GEHC
38.1B USD
41%
14%
11%
No Stocks Found

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
Biosynex SA Competitors

Country Company Market Cap ROE ROA ROCE ROIC
FR
Biosynex SA
PAR:ALBIO
9.2m EUR
-96%
-40%
-67%
-40%
US
Abbott Laboratories
NYSE:ABT
210.2B USD
31%
18%
12%
20%
US
Intuitive Surgical Inc
NASDAQ:ISRG
199.7B USD
17%
15%
17%
22%
US
Boston Scientific Corp
NYSE:BSX
136.4B USD
13%
7%
11%
9%
US
Stryker Corp
NYSE:SYK
133.6B USD
14%
6%
14%
12%
IE
Medtronic PLC
NYSE:MDT
129.1B USD
10%
5%
8%
7%
DE
Siemens Healthineers AG
XETRA:SHL
48.4B EUR
12%
5%
10%
6%
US
IDEXX Laboratories Inc
NASDAQ:IDXX
56.2B USD
65%
31%
58%
35%
US
Becton Dickinson and Co
NYSE:BDX
54.6B USD
7%
3%
7%
6%
US
Edwards Lifesciences Corp
NYSE:EW
48.7B USD
14%
10%
14%
16%
US
GE Healthcare Technologies Inc
NASDAQ:GEHC
38.1B USD
24%
6%
11%
8%
No Stocks Found

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less